Pharma Mar, S.A. (BME:PHM)

Market Cap	1.37B -20.8%
Revenue (ttm)	179.28M +7.3%
Net Income	34.01M +5,367.0%
EPS	1.95
Shares Out	17.21M
PE Ratio	40.83
Forward PE	27.20
Dividend	0.80 (1.00%)
Ex-Dividend Date	Jun 25, 2025

Volume	32,188
Average Volume	28,557
Open	79.15
Previous Close	79.65
Day's Range	78.00 - 79.50
52-Week Range	65.00 - 105.80
Beta	0.44
RSI	52.99
Earnings Date	Feb 27, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PHM

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.